18F—FDG和18F—FLTPET对肿瘤放化疗疗效评价的实验研究  

The experimental study on 18F-FDG and 18F-FLT PET in assessing the outcome of cancer chemotherapy

作　　者：江茂情[1] 吴华[1] 

机构地区：[1]福建省厦门市厦门大学附属第一医院核医学科闽南PET中心,361005

出　　处：《国际放射医学核医学杂志》2011年第3期146-151,共6页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：福建省自然科学基金重点项目（2008-59-11）;厦门市科技计划指导性项目（3502720077056）

摘　　要：PET可从分子水平观察细胞生物学行为。目前，临床上最常崩的葡萄糖代谢显像剂是18F-FDG，而最常用的细胞增殖显像剂是3＇-脱氧-3，-18F氟胸腺嘧啶（18F-FLT）。这两种显像剂在肿瘤的诊断和分期方面已有深入广泛的研究，而在治疗后疗效评价方面的研究近年也很受重视，特别是肿瘤在放化疗前后对18F-FDG和18F-FLT摄取值的变化与肿瘤体积及细胞增殖和细胞周期之间的关系、该文就18F-FDG和18F-FLT在肿瘤放化疗疗效评价中的实验研究进行综述。PET can observe the biological behavior of cell at the molecular level. 18F-FDG is the most widely used glueose metabolic imaging agent. 3-Deoxy-3-[18F] fluorothymidine （18F-FLT） is the most commonly used cell proliferation imaging agent. They both have been deeply researched in the diagnosis and slaging of tunlor. In recent years, researchers have paid more attention to monitoring the outcome of tumor therapy, especially to the relation between the uptake value variation of 18F-FDG, 18F-FLT before and during radiochemotherapy anti lumor volume, cell proliferation, and cell cycle. This article was a research summary, of the assessment of 18F-FDG and 18F-FLT in the outcome of cancer chemotherapy.

关 键 词：肿瘤 氟脱氧葡萄糖F18 氟胸腺嘧啶F18 正电子发射断层显像术 

分 类 号：R730.44[医药卫生—肿瘤]